Longeveron (LGVN) EPS (Weighted Average and Diluted) (2021 - 2026)
Longeveron (LGVN) recorded quarterly EPS (Weighted Average and Diluted) of -$0.19 in Q1 2026, up 13.64% quarter-over-quarter from -$0.22 in Q4 2025, and up 44.12% on a YoY basis from -$0.13 in Q1 2025.
Longeveron (LGVN) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Longeveron's EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.19 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 44.12% year-over-year to -$0.19; the TTM figure through Mar 2026 stood at -$1.13 (up 53.31% YoY), while the FY2025 annual figure was -$1.29, up 50.76% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.19 for Q1 2026 at Longeveron, up from -$0.22 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2024 to a low of -$2.93 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.98 across 5 years, with a median of -$0.34 in 2024.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) plunged 1281.42% in 2023, then surged 103.07% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then slumped by 1278.49% to -$2.93 in 2023, then jumped by 103.07% to $0.09 in 2024, then plunged by 344.44% to -$0.22 in 2025, then advanced by 13.64% to -$0.19 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.19 (Q1 2026), -$0.22 (Q4 2025), and -$0.39 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -0.22 |
| Sep 30, 2025 | -0.39 |
| Jun 30, 2025 | -0.33 |
| Mar 31, 2025 | -0.34 |
| Dec 31, 2024 | 0.09 |
| Sep 30, 2024 | -0.34 |
| Jun 30, 2024 | -1.83 |
| Mar 31, 2024 | -1.61 |
| Dec 31, 2023 | -2.93 |
| Sep 30, 2023 | -2.79 |
| Jun 30, 2023 | -2.67 |
| Mar 31, 2023 | -2.24 |
| Dec 31, 2022 | -0.21 |
| Sep 30, 2022 | -0.25 |
| Jun 30, 2022 | -0.20 |
| Mar 31, 2022 | -0.16 |
| Dec 31, 2021 | -0.21 |
| Sep 30, 2021 | -0.26 |
| Jun 30, 2021 | -0.28 |